cAMP responsive element binding protein 3 like 3Genealiases: CREB-H · CREBH · HYST1481 · HYTG2
Q-omics provides the consensus-scored CREB3L3 profile across patient tissues and cancer cell-line models. CREB3L3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CREB3L3 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, CREB3L3 RNA expression shows 12,698 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, and ESCA as cancer lineages where CREB3L3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CREB3L3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CREB3L3 survival associations across molecular data types. CREB3L3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CREB3L3 RNA expression–survival associations across cancer types. High CREB3L3 expression shows unfavorable associations in LUSC and MESO, but favorable associations in KIRC, ACC, HNSC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CREB3L3 RNA expression.
This table summarizes CREB3L3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CREB3L3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CREB3L3 shows lower tumor expression in COAD, KIRP, READ, CHOL and KICH and higher tumor expression in KIRC. The KIRC box plot shows higher CREB3L3 RNA expression in tumor versus normal tissue (log2 FC = +2.921, t-test p < 0.001).
This table shows molecular features associated with CREB3L3 in patient tissues and cancer cell lines. In patient samples, CREB3L3 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CREB3L3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
